Notice
Recent Posts
Recent Comments
Link
| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
Tags
- 비만치료제
- Nash
- Viking Therapeutics
- tirzepatide
- Semaglutide
- VKTX
- tern-601
- Novo Nordisk
- ct-996
- VK2735
- glp-1 비만
- 제약바이오
- orforglipron
- CAR-T
- GLP-1
- Mash
- 경구용 glp-1
- 노보노디스크
- 자가면역질환 치료제
- Efruxifermin
- GLP-1 치료제
- il-17 inhibitor
- CAR-T in autoimmune
- lilly
- danuglipron
- 바이오스터디
- Pegozafermin
- gsbr-1290
- GLP-1치료제
- GPCR
Archives
- Today
- Total
목록2024/07/25 (1)
제약바이오 츄롸이츄롸이!~
Viking Therapeutics (NASDAQ: VKTX) - 24년 2분기 실적발표 2Q24
https://ir.vikingtherapeutics.com/2024-07-24-Viking-Therapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateConference call scheduled for 4:30 p.m. ET today VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24 Oral VK2735 Phase 2 Study in Ob..
개별 스터디
2024. 7. 25. 10:30